Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation

S. Mizuta, Y. Ito, A. Kohno, H. Kiyoi, K. Miyamura, M. Tanimoto, J. Takamatsu, T. Naoe, Y. Morishima, R. Ueda, H. Saito

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We have investigated whether the extent of residual leukemia at bone marrow harvest can predict subsequent relapse after autologous bone marrow transplantation (BMT). A total of 29 pre- and post-purged marrow samples from 15 patients with high-risk common acute lymphoblastic leukemia were examined. An accurate quantitation of residual disease was achieved by phage library assay using polymerase chain reaction to amplify the third complementarity determining region of the immunoglobulin gene. The estimated rate of disease-free survival at 3 years was significantly higher for the patients with less than 5% residual disease among total B cells than for those with greater than 5% before purging (87.5% vs 0%, P = 0.0013). Furthermore, among patients with subsequent relapse, there was a linear correlation between the quantitated residual tumor burden of pre-purged marrow and remission duration after BMT (r2 = 0.888). An accurate quantitative assessment of residual disease in the autograft has a high predictive value for subsequent relapse. A serial assay of residual disease would help us to individualize the treatment for each patient after induction or consolidation therapy.

Original languageEnglish
Pages (from-to)777-784
Number of pages8
JournalBone Marrow Transplantation
Volume24
Issue number7
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Autologous Transplantation
Residual Neoplasm
Tumor Burden
Bone Marrow Transplantation
Bone Marrow
Recurrence
Complementarity Determining Regions
Immunoglobulin Genes
Autografts
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bacteriophages
Disease-Free Survival
Leukemia
B-Lymphocytes
Polymerase Chain Reaction
Therapeutics

Keywords

  • Autologous BMT
  • B-lineage ALL
  • CDR3
  • Ex vivo purging
  • Minimal residual leukemia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. / Mizuta, S.; Ito, Y.; Kohno, A.; Kiyoi, H.; Miyamura, K.; Tanimoto, M.; Takamatsu, J.; Naoe, T.; Morishima, Y.; Ueda, R.; Saito, H.

In: Bone Marrow Transplantation, Vol. 24, No. 7, 1999, p. 777-784.

Research output: Contribution to journalArticle

Mizuta, S, Ito, Y, Kohno, A, Kiyoi, H, Miyamura, K, Tanimoto, M, Takamatsu, J, Naoe, T, Morishima, Y, Ueda, R & Saito, H 1999, 'Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation', Bone Marrow Transplantation, vol. 24, no. 7, pp. 777-784.
Mizuta, S. ; Ito, Y. ; Kohno, A. ; Kiyoi, H. ; Miyamura, K. ; Tanimoto, M. ; Takamatsu, J. ; Naoe, T. ; Morishima, Y. ; Ueda, R. ; Saito, H. / Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. In: Bone Marrow Transplantation. 1999 ; Vol. 24, No. 7. pp. 777-784.
@article{22a416e816a04e1d872caa0aeb20ee76,
title = "Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation",
abstract = "We have investigated whether the extent of residual leukemia at bone marrow harvest can predict subsequent relapse after autologous bone marrow transplantation (BMT). A total of 29 pre- and post-purged marrow samples from 15 patients with high-risk common acute lymphoblastic leukemia were examined. An accurate quantitation of residual disease was achieved by phage library assay using polymerase chain reaction to amplify the third complementarity determining region of the immunoglobulin gene. The estimated rate of disease-free survival at 3 years was significantly higher for the patients with less than 5{\%} residual disease among total B cells than for those with greater than 5{\%} before purging (87.5{\%} vs 0{\%}, P = 0.0013). Furthermore, among patients with subsequent relapse, there was a linear correlation between the quantitated residual tumor burden of pre-purged marrow and remission duration after BMT (r2 = 0.888). An accurate quantitative assessment of residual disease in the autograft has a high predictive value for subsequent relapse. A serial assay of residual disease would help us to individualize the treatment for each patient after induction or consolidation therapy.",
keywords = "Autologous BMT, B-lineage ALL, CDR3, Ex vivo purging, Minimal residual leukemia",
author = "S. Mizuta and Y. Ito and A. Kohno and H. Kiyoi and K. Miyamura and M. Tanimoto and J. Takamatsu and T. Naoe and Y. Morishima and R. Ueda and H. Saito",
year = "1999",
language = "English",
volume = "24",
pages = "777--784",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation

AU - Mizuta, S.

AU - Ito, Y.

AU - Kohno, A.

AU - Kiyoi, H.

AU - Miyamura, K.

AU - Tanimoto, M.

AU - Takamatsu, J.

AU - Naoe, T.

AU - Morishima, Y.

AU - Ueda, R.

AU - Saito, H.

PY - 1999

Y1 - 1999

N2 - We have investigated whether the extent of residual leukemia at bone marrow harvest can predict subsequent relapse after autologous bone marrow transplantation (BMT). A total of 29 pre- and post-purged marrow samples from 15 patients with high-risk common acute lymphoblastic leukemia were examined. An accurate quantitation of residual disease was achieved by phage library assay using polymerase chain reaction to amplify the third complementarity determining region of the immunoglobulin gene. The estimated rate of disease-free survival at 3 years was significantly higher for the patients with less than 5% residual disease among total B cells than for those with greater than 5% before purging (87.5% vs 0%, P = 0.0013). Furthermore, among patients with subsequent relapse, there was a linear correlation between the quantitated residual tumor burden of pre-purged marrow and remission duration after BMT (r2 = 0.888). An accurate quantitative assessment of residual disease in the autograft has a high predictive value for subsequent relapse. A serial assay of residual disease would help us to individualize the treatment for each patient after induction or consolidation therapy.

AB - We have investigated whether the extent of residual leukemia at bone marrow harvest can predict subsequent relapse after autologous bone marrow transplantation (BMT). A total of 29 pre- and post-purged marrow samples from 15 patients with high-risk common acute lymphoblastic leukemia were examined. An accurate quantitation of residual disease was achieved by phage library assay using polymerase chain reaction to amplify the third complementarity determining region of the immunoglobulin gene. The estimated rate of disease-free survival at 3 years was significantly higher for the patients with less than 5% residual disease among total B cells than for those with greater than 5% before purging (87.5% vs 0%, P = 0.0013). Furthermore, among patients with subsequent relapse, there was a linear correlation between the quantitated residual tumor burden of pre-purged marrow and remission duration after BMT (r2 = 0.888). An accurate quantitative assessment of residual disease in the autograft has a high predictive value for subsequent relapse. A serial assay of residual disease would help us to individualize the treatment for each patient after induction or consolidation therapy.

KW - Autologous BMT

KW - B-lineage ALL

KW - CDR3

KW - Ex vivo purging

KW - Minimal residual leukemia

UR - http://www.scopus.com/inward/record.url?scp=0032872250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032872250&partnerID=8YFLogxK

M3 - Article

C2 - 10516682

AN - SCOPUS:0032872250

VL - 24

SP - 777

EP - 784

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -